Gilead Sciences and its cell therapy subsidiary Kite Pharma have agreed a deal to purchase the biotherapeutics company Cell Design Labs.
The preclinical-stage company offers significant expertise in custom cell engineering and is currently developing two proprietary technology platforms: the synthetic gene expression system synNotch and Throttle, which can be used to modulate CAR-T activity using small molecules.
“Gilead Sciences and Kite have agreed to purchase Cell Design Labs, a specialist creator of custom cell engineering solutions.“
It is expected that the addition of these technologies to Kite's existing research and development programmes could lead to the treatment of a broader range of haematological malignancies and solid tumors, while also improving the selectivity and safety of future treatments.
Gilead will acquire all outstanding shares of Cell Design Labs, which includes a stake currently held by Kite, for up to approximately $567 million (423.58 million pounds), including an initial upfront fee of $175 million and additional milestone-based payments of up to $322 million.
Dr John Milligan, Gilead's president and chief executive officer, said: "This acquisition demonstrates our deep commitment to continuing to invest in future innovation in the field of cellular therapy, both internally and externally."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical